EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Soluble tumor necrosis factor receptors in diabetes: risk sensing and receptor-resolved targeting

Qi Zhu, Yu Liu, Chen Yang, Tie Li

Endocrine Journal · 2026 · 73 (8) · 907-922

DOI: 10.1507/endocrj.ej26-0050 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrine Journal, 2026. Verfasst von Qi Zhu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency, Central Hospital Affiliated to Shenyang Medical College, Shenyang 110032, China. Hauptthemen laut MEDLINE: Receptors, Tumor Necrosis Factor, Type I, Diabetic Nephropathies, Diabetes Mellitus, Type 2, Receptors, Tumor Necrosis Factor, Type II. Die Arbeit nennt 93 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Liaoning Provincial Science and Technology Plan Joint Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetes drives a major burden of kidney failure, cardiovascular disease, and premature mortality, yet current clinical markers incompletely capture individual trajectories of organ decline. Soluble tumor necrosis factor receptors 1 and 2 (sTNFR1/2) have emerged as among the most reproducible circulating predictors of diabetic kidney disease progression, retaining prognostic value after adjustment for estimated glomerular filtration rate (eGFR) and albuminuria across multiple cohorts. Prospective studies in type 2 diabetes also associate higher sTNFR1/2 with incident cardiovascular events and all-cause mortality, supporting a systemic risk phenotype that is not fully explained by baseline kidney measures. Mechanistically, recent work has refined the classical view of tumor necrosis factor (TNF) as a generic inflammatory mediator by identifying proximal checkpoints that govern TNFR1 "injury-biased" outputs, including ubiquitination- and lipidation-dependent control of RIPK1, trafficking-dependent restraint of death-receptor signaling, and cross-pathway phosphorylation that retunes downstream complex assembly. In parallel, advances in therapeutic engineering are shifting the field from non-selective TNF neutralization toward receptor-selective modulation, including TNFR1-selective antagonists, allosteric inhibitors, and shedding strategies designed to reduce injury signaling while preserving TNFR2-linked immunoregulatory and reparative programs. This receptor-resolved framework provides a coherent basis for interpreting why soluble receptors outperform circulating TNF as prognostic biomarkers and for developing mechanism-informed interventions in diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Tumor Necrosis Factor, Type IDiabetic NephropathiesDiabetes Mellitus, Type 2Receptors, Tumor Necrosis Factor, Type IIHumansAnimalsSignal TransductionBiomarkersTumor Necrosis Factor-alpha

Stichwörter der Autor:innen

DiabetesDiabetic kidney diseaseSoluble tumor necrosis factor receptorsTumor necrosis factor receptor 1Tumor necrosis factor receptor 2

Substanzen

Receptors, Tumor Necrosis Factor, Type IReceptors, Tumor Necrosis Factor, Type IIBiomarkersTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Department of Emergency, Central Hospital Affiliated to Shenyang Medical College, Shenyang 110032, China.
  • Department of Endocrinology, Central Hospital Affiliated to Shenyang Medical College, Shenyang 110032, China.

Förderung

  • Liaoning Provincial Science and Technology Plan Joint Program

Zitieren

APA

Zhu, Q., Liu, Y., Yang, C., & Li, T. (2026). Soluble tumor necrosis factor receptors in diabetes: risk sensing and receptor-resolved targeting. Endocrine Journal, 73(8), 907-922. https://doi.org/10.1507/endocrj.ej26-0050

Vancouver

Zhu Q, Liu Y, Yang C, Li T. Soluble tumor necrosis factor receptors in diabetes: risk sensing and receptor-resolved targeting. Endocrine Journal. 2026;73(8):907-922. doi:10.1507/endocrj.ej26-0050

BibTeX
@article{Zhu2026,
  author = {Zhu, Qi and Liu, Yu and Yang, Chen and Li, Tie},
  title = {Soluble tumor necrosis factor receptors in diabetes: risk sensing and receptor-resolved targeting},
  journal = {Endocrine Journal},
  year = {2026},
  volume = {73},
  number = {8},
  pages = {907--922},
  doi = {10.1507/endocrj.ej26-0050}
}
Kostenlos starten →